82 results about "S genotyping" patented technology

Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Disclosed are methods and genotyping panels for detecting alleles, genomes, and transcriptomes in admixtures of two individuals.

Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

The present disclosure provides methods and systems for incorporating multiple environmental and genetic risk factors into an individual's genomic profile. Methods include assessing the association between an individual's genotype and at least one disease or condition by incorporating multiple genetic risk factors, environmental risk factors, or a combination of both.

Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's gen type for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Presenting ancestral origin information, comprising: receiving a request to display ancestry data of an individual; obtaining ancestry composition information of the individual, the ancestry composition information including information pertaining to a proportion of the individual's genotype data that is deemed to correspond to a specific ancestry; and presenting the ancestry composition information to be displayed.

Estimating parental contribution of ancestry includes: obtaining a set of ancestry assignment data associated with an individual's genotype data, at least some of the ancestry assignment data indicating that one or more segments of the individual's genotype data is deemed to be associated with a specific ancestry; determining whether in the individual's genotype data there is at least one confirmed region of overlapping ancestry assignment associated with the specific ancestry; in the event that it is determined that there is at least one confirmed region of overlapping ancestry assignment associated with the specific ancestry: specifying that parental contribution of the specific ancestry is made by both parents of the individual; in the event that it is determined that there is no confirmed region of overlapping ancestry assignment associated with the specific ancestry: statistically determining whether the parental contribution to the specific ancestry is made by only one parent of the individual or by both parents of the individual, the determination being based at least in part on one or more lengths of the one or more segments deemed to be associated with the specific ancestry; and outputting information pertaining to the parental contribution to the specific ancestry.

Admixture generation determination includes: obtaining ancestry assignment information associated with an individual's genotype data, the ancestry assignment information at least indicating that a portion of the individual's genotype data is deemed to be associated with a specific ancestry; determining the individual's genetic ancestry summary data corresponding to the specific ancestry; estimating an admixture generation associated with the specific ancestry, the admixture generation indicating a most recent generation or a most recent generation range from which the individual has at least one non-admixed ancestor of the specific ancestry, the estimation including a maximum likelihood determination based at least in part on the individual's genetic ancestry summary data and a recombination model; and outputting the estimated admixture generation.

The present invention relates to an SNP (single nucleotide polymorphism) combination, detection method and kit for detecting liver damage susceptible genotype of an antitubercular drug and belongs to the technical field of medical molecular biological diagnosis; the SNP combination includes 7 SNP sites, and nucleotide sequences of the 7 SNP sites are shown sequentially as in SEQ ID NO. 1-7; the present invention also relates to an SNP detection method, comprising PCR (polymerase chain reaction) amplification and double-labeled probe melting curve analytical reaction, and primer pairs and double-labeled probe sequences for detection of the 7 SNP sites are shown as in SEQ ID NO. 8-20. The SNP site combination, detection method and kit provided herein enables quick, accurate, simple and high-throughput detection for a patient's genotype and prediction for the liver damage risk due to the patient using the antitubercular drug.

The present invention relates to a computer assisted method of providing a personalized assessment of supplement requirements for a human subject in which an individual's genotype is analysed for the presence of alleles at one or more genetic loci which may be associated with risk factors, and the alleles present compared to a first dataset comprising information correlating the presence of individual alleles at genetic loci with a lifestyle risk factor to provide a risk factor associated with the presence of particular alleles in order to generate a personalized assessment of nutritional and therapeutic supplement requirements, which may include a personalized supplementation formula.

The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype.

Estimating parental contribution of ancestry includes: obtaining a set of ancestry assignment data associated with an individual's genotype data, at least some of the ancestry assignment data indicating that one or more segments of the individual's genotype data is deemed to be associated with a specific ancestry; determining whether in the individual's genotype data there is at least one confirmed region of overlapping ancestry assignment associated with the specific ancestry; in the event that it is determined that there is at least one confirmed region of overlapping ancestry assignment associated with the specific ancestry: specifying that parental contribution of the specific ancestry is made by both parents of the individual; in the event that it is determined that there is no confirmed region of overlapping ancestry assignment associated with the specific ancestry: statistically determining whether the parental contribution to the specific ancestry is made by only one parent of the individual or by both parents of the individual, the determination being based at least in part on one or more lengths of the one or more segments deemed to be associated with the specific ancestry; and outputting information pertaining to the parental contribution to the specific ancestry.

A computerized decision support system and method for predicting which of one or more drugs suitable to treat a cancerous condition in a patient are the optimum drug(s), where such selection is based upon the particular patient's genotype. A PCR kit and / or a gene chip detects multiple genes, expressions and / or mutations associated with a particular cancer using a sample of the patient's tissue or blood. A detector accepts the gene chip and analyzes the patient's genotype; and a computerized system using a database which associates patient genotypes and the efficacy and toxicity of various anti-cancer drugs used in treating patients with a particular cancerous condition connected to the detector correlates the output of the detector to the database to provide a recommendation as to which drugs are optimum for treating the patient's cancer.

The invention discloses an HIV-1 genotype and drug resistant mutation site detection kit and application thereof. The kit comprises set of primers detecting to-be-detected HIV-1 genome's genotype and drug resistant mutation site. The set of primers include amplification primer pairs and sequencing primer sets. Experiments prove that the detection kit provided by the invention ensures the detection capability of low-frequency mutant strains, greatly makes up the disadvantages of poor amplification efficiency, low detection rate and low low-frequency mutation detection rate of similar kits imported from abroad to China HIV epidemic strains, has the characteristics of simple and fast operation, high efficiency, economical efficiency and high throughput, etc., not only lays a solid foundation for domestic production of HIV drug resistant detection reagents, but also opens up broad prospect for domestic large-scale detection of HIV virus strain drug resistant situation.

The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and / or for the treatment and / or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient to determine their Val66Met rs6265 polymorphism in BDNF and administering a ketamine, preferably esketamine, preferably intranasal esketamine, according to a dosing regimen matched to the patient's genotype.

The present invention provides methods and tests that allow for the establishment of personalized weight-management programs for an individual based upon the individual's genotype in the glutathione S-transferase pi gene and / or the interleukin-6 gene. Methods are disclosed for determining the individual's genotype, which may be used to select an appropriate therapeutic / dietary program or lifestyle recommendation. Such a personalized weight-management program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-management programs that do not take into account genetic information.

The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

The present invention provides methods for improving desirable animal traits including improved fitness and productivity in dairy animals. Also provided are methods for determining a dairy animal's genotype with respect to multiple markers associated with fitness and / or productivity. The invention also provides methods for selecting or allocating animals for predetermined uses such as progeny testing or nucleus herd breeding, for picking potential parent animals for breeding, and for producing improved progeny animals. Each of the above methods may be further improved through the incorporation of interaction effects between multiple SNPs.

The present invention provides methods for improving desirable dairy traits through the use of a genetic profile. Also provided are methods for determining an animal's genotype with respect to multiple markers used in the analysis of the genetic profile. In some embodiments, the genetic profile includes at least one marker associated with the polled trait. The invention also provides methods for selecting or allocating animal for predetermined uses, for picking potential parent animal for breeding, and for producing improved dairy products.

Embodiments of the present invention provide methods for improving desirable animal traits including the horned / polled phenotype in bovine animals. Also provided are methods for determining a dairy animal's genotype with respect to multiple markers associated with polled, fitness and / or productivity traits. The invention also provides methods for selecting or allocating animals for predetermined uses such as progeny testing or nucleus herd breeding, for picking potential parent animals for breeding, and for producing improved progeny animals. Also provided are methods for identifying genetic markers associated with polled, fitness and / or productivity traits that are in allelic association with the SNPs disclosed herein.

The present disclosure provides methods and systems for assessing an individual's genotype correlations to a phenotype by analyzing the individual's genomic profile and using ancestral data to determine the correlations between genotypes and phenotypes.

The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

The invention discloses a planting method for achieving continuous high and stable almond yield under the intercropping condition. The line spaces of almond trees are determined by utilizing a fixed planting mode, a 3 meters * 7 meters planting mode suitable for intercropping is adopted, S-genotype varieties are adopted for matching, a trimming and pruning technology is adopted for high-trunk layered trees, a fruit tree moisturizing technology is adopted to meet the water demands of the almond trees and inter-planted crops, winter rapes are inter-planted in protective zones among lines to promote fertilization and insemination of the almond trees, a young fruit abscission prevention technology is adopted to decrease fruit abscission of the almond trees, and a growth regulator is applied to promote fruit setting of the almond trees, decrease fruit abscission of the almond trees and promote flower bud differentiation of the almond trees. The technical problems of the disorder fixed planting mode of the almond trees, variety matching without scientific basis, serious intercropping contradiction, severe insufficiency of bees for supplementary pollination, young fruit abscission and unreasonable growth regulator application are solved, accordingly the almond yield in the current year can be ensured, crops inter-planted among lines are not influenced, the purpose of obtaining the yield of the next year is achieved, and high and stable almond yield is achieved.

The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.

A method and system is provided for visualization and pictorial presentation to a user of possible interactions between a prospective drug that is being considered for prescribing to a person and that person's genotype. Genetic information of the person that can affect the manner in which a drug acts on a molecular, physiological or biological function of the body or a tissue, or a manner in which a drug is being metabolized, absorbed, excreted or otherwise eliminated from the body or a tissue by the body or tissue systems, is entered into a computerized device. The computerized device conducts a search of a drug database for drugs that have known interactions with the entered genetic information, and assigns a numeric value to each of a plurality of drugs, either in aggregate, as a class, or individually, in order to quantify the nature, strength and direction of each interaction. The computer sends the assigned numeric values to the computer's output module for their visual presentation to a user as a graph including a panel of columns, or other geometrical structures, whose geometrical characteristics correspond to the assigned numeric values of each drug, in order to facilitate the prospective drug selection by a prescriber on the basis of the totality of drug-gene and / or drug-drug interactions presented to the user as a visual graph.

The present invention provides methods and devices for predicting whether a HIV variant will be resistant to an antiviral drug based on the variant's genotype. In one aspect, methods are provided comprising determining whether a combination of protease inhibitor resistance mutations meet certain conditions, as disclosed herein, thereby assessing the effectiveness of ritonavir-boosted indinavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV resistance are provided.

The present invention relates to methods, kits, probes, and systems for distinguishing between nucleotide variants that are close in proximity on a gene. The methods, kits, probes, and systems can include the use of a small amplicon assay in combination with two unlabeled probes in a high resolution thermal melting analysis of a biological sample containing a locus of interest in order to discern between disease-causing and benign variants that are close in proximity on a gene within the biological sample. The present invention also relates to method of detecting a disease in a patient based on the patient's genotype by determining whether the patient has a disease-causing variant at a locus of interest. The signature melt curves produced by the unlabeled probe tests can be analyzed using HRMA software to distinguish between disease-causing and benign variants that are close in proximity on a gene within the biological sample.

The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU.

The present disclosure provides methods and systems for incorporating multiple environmental and genetic risk factors into an individual's genomic profile. Methods include assessing the association between an individual's genotype and at least one disease or condition by incorporating multiple genetic risk factors, environmental risk factors, or a combination of both.

The invention discloses a method for identifying S genotype of an apple and a special reagent kit thereof. The method uses the genomic DNA of an apple variety to be detected as a template and amplification is carried out by the use of primer pairs for identifying the S genotype of the apple variety so as to determine the S genotype of the apple variety to be detected according to the amplification result. By the method, the selfed incompatible S genotype of the apple variety can be fast identified, and pollenizers can be selected through the S genotype thereof. Therefore, the method has important application value on apple planting and hybridization research.